A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019.
作者信息
Zhang Fengqin, Wei Yanqiu, He Li, Zhang Huilan, Hu Qiongjie, Yue Huihui, He Jianhan, Dai Huaping
机构信息
Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 10029, China.
出版信息
Chin Med J (Engl). 2021 Dec 1;135(3):368-370. doi: 10.1097/CM9.0000000000001614.
Abstract
摘要
相似文献
1
A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019.吡非尼酮治疗住院成年重症2019冠状病毒病患者的试验。
Chin Med J (Engl). 2021 Dec 1;135(3):368-370. doi: 10.1097/CM9.0000000000001614.
2
Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.
Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228-9; author reply 1229. doi: 10.1164/ajrccm.172.9.951.
3
Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.吡非尼酮在转化生长因子-β（TGF-β）途径和急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染其他炎症途径中的作用：理论观点。
Pharmacol Rep. 2021 Jun;73(3):712-727. doi: 10.1007/s43440-021-00255-x. Epub 2021 Apr 21.
4
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.吡非尼酮的疗效与特发性肺纤维化的疾病严重程度：日本III期试验的扩展分析
Respir Investig. 2015 Nov;53(6):279-87. doi: 10.1016/j.resinv.2015.06.002. Epub 2015 Oct 23.
5
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.吡非尼酮可减少特发性肺纤维化患者与呼吸相关的住院次数。
Am J Respir Crit Care Med. 2017 Sep 15;196(6):756-761. doi: 10.1164/rccm.201701-0091OC.
6
The questionable efficacy of pirfenidone in IPF.
Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228. doi: 10.1164/ajrccm.172.9.950.
7
Pirfenidone for the treatment of idiopathic pulmonary fibrosis.吡非尼酮用于治疗特发性肺纤维化。
Expert Rev Respir Med. 2014 Oct;8(5):539-45. doi: 10.1586/17476348.2014.915750. Epub 2014 Aug 12.
8
A pilot study in patients with established advanced liver fibrosis using pirfenidone.一项在已确诊为晚期肝纤维化患者中使用吡非尼酮的试点研究。
Gut. 2006 Nov;55(11):1663-5. doi: 10.1136/gut.2006.107136.
9
Pirfenidone: in idiopathic pulmonary fibrosis.吡非尼酮：在特发性肺纤维化中的应用。
Drugs. 2011 Sep 10;71(13):1721-32. doi: 10.2165/11207710-000000000-00000.
10
Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.吡非尼酮治疗严重特发性肺纤维化的安全性和有效性：一项真实世界的观察性研究。
Pulm Pharmacol Ther. 2017 Oct;46:48-53. doi: 10.1016/j.pupt.2017.08.011. Epub 2017 Aug 24.
引用本文的文献
1
Dual threat: Susceptibility mechanisms and treatment strategies for COVID-19 and bacterial co-infections.双重威胁：新型冠状病毒肺炎与细菌合并感染的易感性机制及治疗策略
Comput Struct Biotechnol J. 2025 May 22;27:2107-2122. doi: 10.1016/j.csbj.2025.05.033. eCollection 2025.
2
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial.吡非尼酮治疗新冠后肺纤维化（FIBRO-COVID）：一项2期随机临床试验
Eur Respir J. 2025 Apr 24;65(4). doi: 10.1183/13993003.02249-2024. Print 2025 Apr.
3
Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review.吡非尼酮在纤维化间质性肺疾病及其他方面的应用：综述
Front Med (Lausanne). 2024 Aug 6;11:1411279. doi: 10.3389/fmed.2024.1411279. eCollection 2024.
4
The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks.抗纤维化药物对 COVID-19 患者急性呼吸衰竭的影响：来自 TriNetX 美国合作网络的回顾性队列研究。
BMC Pulm Med. 2024 Apr 2;24(1):160. doi: 10.1186/s12890-024-02947-5.
5
Pharmacological approaches to pulmonary fibrosis following COVID-19.新冠病毒感染后肺纤维化的药理学治疗方法。
Front Pharmacol. 2023 Jun 15;14:1143158. doi: 10.3389/fphar.2023.1143158. eCollection 2023.
6
Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology.炎症小体：COVID-19 病理生理学地平线上的一颗冉冉升起的新星。
Front Immunol. 2023 May 12;14:1185233. doi: 10.3389/fimmu.2023.1185233. eCollection 2023.
7
Post-COVID Interstitial Lung Disease and Other Lung Sequelae.新冠后间质性肺病及其他肺部后遗症。
Clin Chest Med. 2023 Jun;44(2):263-277. doi: 10.1016/j.ccm.2022.11.019. Epub 2023 Mar 3.
8
Microvascular significance of TGF-β axis activation in COVID-19.转化生长因子-β轴激活在新型冠状病毒肺炎中的微血管意义
Front Cardiovasc Med. 2023 Jan 6;9:1054690. doi: 10.3389/fcvm.2022.1054690. eCollection 2022.
9
The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia.新冠病毒诱发的机化性肺炎这一隐匿的大流行疾病
Pharmaceuticals (Basel). 2022 Dec 16;15(12):1574. doi: 10.3390/ph15121574.
10
Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm.吡非尼酮对经历细胞因子风暴的COVID-19患者肺纤维化风险的影响。
Healthcare (Basel). 2022 Nov 28;10(12):2387. doi: 10.3390/healthcare10122387.
Zotero 插件